What is claimed is:

- 1. A compound 8 to 50 nucleobases in length targeted to a 5' UTR, coding, 3' UTR or intron region of a nucleic acid molecule encoding Phospholipase A2, group IIA (synovial), wherein said compound specifically hybridizes with and inhibits the expression of Phospholipase A2, group IIA (synovial).
- 2. The compound of claim 1 which is an antisense oligonucleotide.
- 3. The compound of claim 2 wherein the antisense oligonucleotide has a sequence comprising SEQ ID NO: 19, 20, 21, 22, 23, 25, 27, 28, 29, 33, 34, 35, 39, 40, 41, 42, 44, 45, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 63, 64, 68, 69, 70, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 84, 85, 87, 88, 89, 91, 93, 94, 95, 98, 101, 102, 104, 108, 110, 112, 116, 120, 121, 138, 139, 140, 148, 149, 153, 156, 158, 159, 161, 162, 163, 167, 171 or 173.
- 4. The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified internucleoside linkage.
- 5. The compound of claim 4 wherein the modified internucleoside linkage is a phosphorothicate linkage.
- 6. The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified sugar moiety.
- 7. The compound of claim 6 wherein the modified sugar moiety is a 2'-O-methoxyethyl sugar moiety.
- 8. The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified nucleobase.
- 9. The compound of claim 8 wherein the modified nucleobase is a 5-methylcytosine.
- 10. The compound of claim 2 wherein the antisense oligonucleotide is a chimeric oligonucleotide.

- 11. A compound 8 to 50 nucleobases in length which specifically hybridizes with at least an 8-nucleobase portion of an active site on a nucleic acid molecule encoding Phospholipase A2, group IIA (synovial).
- 12. A composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier or diluent.
- 13. The composition of claim 12 further comprising a colloidal dispersion system.
- 14. The composition of claim 12 wherein the compound is an antisense oligonucleotide.
- 15. A method of inhibiting the expression of Phospholipase A2, group IIA (synovial) in cells or tissues comprising contacting said cells or tissues with the compound of claim 1 so that expression of Phospholipase A2, group IIA (synovial) is inhibited.
- 16. A method of treating an animal having a disease or condition associated with Phospholipase A2, group IIA (synovial) comprising administering to said animal a therapeutically or prophylactically effective amount of the compound of claim 1 so that expression of Phospholipase A2, group IIA (synovial) is inhibited.
- 17. The method of claim 16 wherein the disease or condition is inflammation.
- 18. The method of claim 16 wherein the disease or condition is cancer.
- 19. The method of claim 16 wherein the disease or condition is psoriasis.
- 20. The method of claim 16 wherein the disease or condition is diabetes.